Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Zolnierek

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reviews|September 28, 2000
Antisense therapy in cancerW Pawlak, J Zolnierek, T Sarosiek, et al.
Expert Opinion on Biological Therapy|May 5, 2007
Recent developments in renal cell cancer immunotherapyP J Wysocki, J Zolnierek, C Szczylik, et al.
Neoplasma|May 6, 2005
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experienceP Rzepecki, J Zolnierek, T Sarosiek, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|October 6, 2007
Multimodality treatment of germ cell cancer patients who had progression or relapse after high dose chemotherapy and autologous bone marrow transplantationT Sarosiek, P Rzepecki, P Langiewicz, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reviews|September 28, 2000
Antisense therapy in cancerW Pawlak, J Zolnierek, T Sarosiek, et al.
Expert Opinion on Biological Therapy|May 5, 2007
Recent developments in renal cell cancer immunotherapyP J Wysocki, J Zolnierek, C Szczylik, et al.
Neoplasma|May 6, 2005
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experienceP Rzepecki, J Zolnierek, T Sarosiek, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|October 6, 2007
Multimodality treatment of germ cell cancer patients who had progression or relapse after high dose chemotherapy and autologous bone marrow transplantationT Sarosiek, P Rzepecki, P Langiewicz, et al.
Pageof 1